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ABSTRACT
Diffuse large B cell lymphoma (DLBCL) is the most frequent lymphoma 
accounting for more than the 30% of the cases. Involvement of extranodal sites, 
such as bone marrow and central nervous system, is associated with poor prognosis. 
A contribution of the chemokine system in these processes is assumed as it is known 
as a critical regulator of the metastatic process in cancer. The atypical chemokine 
receptor 3 (ACKR3), which does not couple to G-proteins and does not mediate cell 
migration, acts as a scavenger for CXCL11 and CXCL12, interfering with the tumor 
homing CXCL12/CXCR4 axis. Here, functional expression of ACKR3 in DLBCL cells 
was necessary for colonization of the draining lymph node in an in vivo subcutaneous 
lymphoma model. Moreover, in a disseminated in vivo lymphoma model, ACKR3 
expression was required for bone marrow and brain invasion and local tumor growth. 
The present data unveil ACKR3 as potential therapeutic target for the control of tumor 
dissemination in DLBCL.
INTRODUCTION
The importance of the chemokine system for 
orchestrating the homeostatic and inflammatory 
leucocyte trafficking is amply described. In addition, 
the chemokine system has critical roles during normal 
development as well as in pathological tissue growth and 
aberrant activity of the system was found to have diverse 
pathogenic consequences, including the onset and the 
course of diseases [1, 2]. A hallmark of chemokine 
induced signaling is stimulation of cell migration and 
requires binding to cognate cell surface chemokine 
receptors, members of the rhodopsin family of G-protein 
coupled receptors (GPCRs) [3]. A group of structurally 
and phylogenetically related chemokine binding proteins 
was recently classified as atypical chemokine receptors 
(ACKRs), based on their inability to couple and activate 
heterotrimeric G-proteins. Presumably due to the lack 
of G-protein coupling ACKRs are unable to stimulate 
cell migration [4, 5]. The main function of ACKRs is to 
scavenge chemokines. The ACKRs are critical players in 
the resolution of inflammation by removing the excess 
of chemokines and markedly contribute to gradient 
formation promoting efficient leukocyte trafficking 
[6–8].
ACKR3 is a scavenger of CXCL11 and CXCL12, 
which are ligands of the typical receptors CXCR3 
and CXCR4, respectively. Noteworthy, ACKR3 has 
approximately 10 fold higher affinity for CXCL12 than 
CXCR4 (IC50=0.4 nM vs. 3.6 nM) [9–11]. During B cell 
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development ACKR3 is upregulated at the plasmablast 
stage and due to its scavenging activity was suggested 
to license these cells to leave the CXCL12-rich 
environment of germinal centers (GC) in B cell follicles 
of secondary lymphoid organs [12]. On the other hand, 
local scavenging of CXCL12 by ACKR3 markedly 
contributes to the formation of functional chemotactic 
gradients [7, 13, 14].
CXCR4 and ACKR3 as well as CXCL12 are 
frequently overexpressed in human cancers where they 
contribute to tumor growth and metastasis formation [1, 
15–18]. Elevated expression of CXCR4 is frequently 
associated with unfavorable prognosis [19]. Similarly, 
ACKR3 was found to be upregulated in many solid tumors 
including breast, lung, prostate and hepatocellular cancers, 
neuroblastoma, glioma, and cutaneous squamous cell 
carcinoma [20–27].
Nevertheless, the molecular mechanism of ACKR3 
in tumor formation is less clear and may vary between 
cancers types. In some tumors ACKR3 was shown to 
affect CXCL12/CXCR4 signaling [18, 28, 29]. ACKR3 
can also indirectly regulate CXCR4 surface expression 
by modulating CXCL12 levels. In breast cancer, ACKR3 
expressed in trans can modulate CXCL12 levels leading 
to altered CXCR4-dependent tumor growth [24]. In the 
absence of ACKR3, CXCL12 can accumulate and lead 
to the downregulation and degradation of CXCR4 [30, 
31]. ACKR3 can also influence tumor vascularization 
by regulating CXCL12 levels [32]. The described 
controversial roles of ACKR3 in tumor formation and 
metastasis do not allow making general predictions.
Few studies address the role of ACKR3 in 
hematological cancers. The receptor is markedly 
upregulated in acute lymphoblastic leukemia (ALL) 
[33] and acute myeloid leukemia (AML) [34]. In 
mucosa-associated lymphoid tissue (MALT) neoplasms 
upregulation of ACKR3 and concomitant downregulation 
of CXCR4 could play a role in the transformation to 
diffuse large B-cell lymphoma (DLBCL) [35, 36]. 
Typically, DLBCL arise from GC cells, either from 
centroblast leading to GC B-cell like (GCB), or from 
plasmablasts leading to activated B cell-type (ACB) 
lymphomas [37]. DLBCL is the most frequent lymphoma 
and accounts for about 30% of all newly diagnosed 
cases and frequently involves extranodal sites [37]. 
Invasion of bone marrow occurs in 10-15% of patients 
[38], whereas involvement of the central nervous system 
(CNS) occurs in about 5% of cases and is associated with 
very poor prognosis [39]. Here we investigated the role 
of ACKR3 on the DLBCL cell line VAL. In a xenograft 
model in immunodeficient mice cell surface expression of 
functional active ACKR3 becomes markedly upregulated 
without alterations of its mRNA expression. Genetic 
ablation of ACKR3 by CRISPR/Cas9 attenuates cell 
migration in vivo and markedly limits tissues invasion of 
the lymphoma cells.
RESULTS
Subcutaneous conditioning increases surface 
expression of ACKR3
The observation that ACKR3 is upregulated in 
human plasmablasts, prompted us to interrogate the 
expression of its mRNA in human DLBCL lines. The 
transcript of ACKR3 was found in several, but not all 
DLBCL lines tested. By semi quantitative PCR analysis 
VAL cells showed a moderate, but consistent expression 
of ACKR3 and were therefore selected for the subsequent 
experiments (Supplementary Figure 1A). Despite being 
clearly expressed at the mRNA level, only about 15% 
of VAL cells expressed ACKR3 on the cell surface. 
FACS analysis using different monoclonal antibodies, 
i.e. clones 9C4 [11] (Figure 1A) and clone 11G8 [10] 
(Supplementary Figure 1B), revealed the presence of 
two populations with and without ACKR3 present on the 
plasma membrane. By contrast, all VAL cells expressed 
similar levels of CXCR4 on the cell surface, which renders 
them a suitable model for studying ACKR3 modulation 
of the CXCR4/CXCL12 axis. When VAL cells were 
sorted for ACKR3 surface expression both populations, 
ACKR3+ and ACKR3-, showed similar levels of mRNA 
transcripts (Supplementary Figure 1B). The finding 
suggests that in VAL cells ACKR3 may preferentially 
localize in intracellular compartments as reported for 
other leukocytes [33, 34, 40]. Both, ACKR3 positive 
and negative sorted cells reverted to the same phenotype 
of unsorted cells after 2-3 weeks of culture indicating a 
dynamic equilibrium of the populations (data not shown). 
Tumor environment is often characterized by reduced 
oxygen supply. In vitro, the hypoxia-mimetics cobalt 
chloride and DMOG [41] efficiently upregulate CXCR4, 
but not ACKR3, on VAL cells (Supplementary Figure 2), 
indicating that compartmentalization of the typical and 
atypical chemokine receptors is controlled by different 
mechanisms and is intrinsic to the cells.
The aggressiveness of DLBCL cell lines 
RIVA and TOLEDO, when injected into NOD/SCID 
immunosuppressed mice, positively correlated with 
CXCR4 surface expression. Conditioning of RIVA 
cells in subcutaneous localized tumors further triggered 
tissue invasiveness and lethality, when such cells were 
injected intravenously [42]. However, compared to RIVA 
cells, VAL cells expressed higher levels of ACKR3, but 
similar levels of CXCR4 mRNA (not shown) and did not 
upregulate CXCR4 surface expression when grown in 
subcutaneous xenografts in NOD/SCID/common γ-chainko 
mice (Figure 1A and 1B). Moreover, Figure 1A and 1B 
reveals that all Val cells expressed similar percentages of 
CXCR4+ cells; however, the in vivo passage moderately 
decreased the surface expression level of CXCR4 
on the ACKR3+ VAL cells (Figure 1B). By contrast, 
ACKR3 became markedly upregulated as up to 50% of 
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Figure 1: ACKR3 surface expression is upregulated on ex vivo cells without affecting ACKR3 gene transcription levels. 
(A) Surface expression of ACKR3 and CXCR4 on VAL cells in culture or extracted from localized xenografts (ex vivo) grown in NOD/
SCID/common γ-chainko mice. For FACS analysis cells were stained with the anti-human ACKR3 mAb 9C4 and the anti-human CXCR4 
mAb 12G5. Representative data are shown for one of six xenografts from three independent experiments (n=5-16 mice per experiment). 
Quantification of the percentage of ACKR3-expressing cells reported as mean ±SD. (B) Data as in A presented as histograms to reveal 
differences in relative receptor surface expression. Left, gray histograms VAL cells ex vivo, black histograms VAL cells in culture. Right, 
quantification of the mean fluorescence intensities (MFI) reported as mean ±SD. Data from three independent experiments. Statistical 
analysis (*** = p<0.0001; ** = p<0.001; * = p<0.05) was performed with two-tailed Student’s t-test. (C) Relative ACKR3 transcription levels 
of human CD19+-enriched VAL cells extracted from five different xenografts (VAL ex vivo 1 to 5) and VAL cells in culture assessed by RT-
PCR. Results were normalized against human TBP1 mRNA levels and are expressed as 2-ΔCt. Histograms report mean ACKR3 expression 
± SEM measured as triplicates. Representative plot from one of two independent experiments.
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the conditioned cells (ex vivo) expressed the receptor 
(Figure 1A and 1B), indicating that after localized tumor 
passage the presence of two populations existed, namely 
ACKR3+/CXCR4+ and ACKR3-/CXCR4+cells. After 2-3 
weeks of in vitro culture, ex vivo cells were phenotypically 
indistinguishable from the starting cells, indicating that the 
environment influences ACKR3 surface expression. More 
importantly, the high surface ACKR3 expression of ex vivo 
cells isolated from localized tumors, was not accompanied 
by variations of ACKR3 gene transcripts measured by RT-
PCR (Figure 1C) mirroring the expression of ACKR3+ 
sorted cells.
ACKR3 is functional on ex vivo VAL cells
Different functional assays were used to test ACKR3 
activity on VAL cells. Previously we have shown that 
ACKR3-mediated uptake of ligands is a reliable method 
to determine its activity on B cells [43]. In order to assess 
ACKR3-mediated chemokine binding and internalization 
in the presence of CXCR4, an ACKR3-specific chimeric 
chemokine (CXCL11_12), consisting of CXCL12 body 
with the N-terminal sequence of CXCL11, the second 
ligand of ACKR3 was generated, in line with the notion 
that modifications of the N-terminus abrogate binding of 
CXCL12 to CXCR4 [44]. In fact, CXCL11_12 selectively 
binds ACKR3, but not CXCR4 and CXCR3 (MT and 
ER, unpublished). Ex vivo VAL cells incubated with 50 
nM of CXCL11_12 labeled with Atto565 [45] efficiently 
internalized the chimeric chemokine (Figure 2A). Uptake 
was markedly attenuated by the mAb 9C4, but not by the 
small molecule AMD3100 and the mAb 12G5, which 
both target CXCR4, indicating that CXCL11_12 was 
internalized by the scavenger ACKR3. Interestingly, 
incubation with the CXCR4 inhibitor isothiourea 
NIBR1816 [46] significantly affected CXCL11_12 uptake. 
NIBR1816 was shown to insert into the binding cavity of 
CXCR4 and to interact with selective side chains [47], 
that are considered critical for receptor activation. These 
residues (e.g. Asp97 and Asp187) are not conserved in 
ACKR3, suggesting a different binding mechanism to the 
scavenger, that interferes with CXCL11_12 uptake. When 
the cells were incubated with CXCL12 instead, the uptake 
became markedly sensitive to AMD3100 and the mAb 
12G5, but remained sensitive to mAb 9C4 indicating that 
internalization was mediated by both, CXCR4 and ACKR3. 
In agreement with the internalization of CXCL11_12, the 
strongest inhibition of CXCL12 uptake was observed in the 
presence of NIBR1816 in line with the conclusion that the 
compound targets both receptors (Figure 2A).
Next, binding and uptake of an ACKR3-specific 
antibody was investigated. For antibody binding to surface 
expressed receptors VAL cells were kept at 4°C, whereas 
incubation at 37°C allowed receptor internalization. 
In accordance with the higher surface expression of 
ACKR3, ex vivo VAL cells internalized more efficiently 
fluorophore-conjugated ACKR3-specific mAb 11G8 
than cells kept in culture (Figure 2B). Internalization 
was confirmed by the resistance of antibody-derived 
fluorescence to a brief acidic wash which removes surface 
bound mAb [48]. Moreover, at 4°C when endocytic 
processes are blocked, more antibody bound to ex vivo 
cells compared to cells kept in culture recapitulating the 
higher ACKR3 surface expression (Figure 2B).
Creation of VAL ACKR3ko cells with the 
CRISPR/Cas9 system
To test the role of ACKR3 in tumor growth of VAL 
cells, the genome editing CRISPR/Cas9 technology was 
used to eliminate the receptor [49]. With this method 
the ACKR3 gene was disrupted and cyan fluorescent 
protein (CFP) inserted. Genomic PCR analysis of a 
CFP positive clone revealed the complete modification 
of the ACKR3 gene locus of all alleles (Supplementary 
Figure 3). Figure 3A shows the FACS analysis of VAL 
ACKR3wt and ACKR3ko cells, which were kept in culture 
or conditioned in a localized subcutaneous xenograft. 
Typical staining of ACKR3 was observed in wild type 
VAL cells (Figure 1A), which was completely abolished 
in ACKR3ko cells and was also absent in corresponding 
ex vivo cells. Cells lacking ACKR3 gene completely lost 
the ability to uptake CXCL11_12. As control mouse 
300.19 pre-B cells which lack ACKR3 expression were 
used as controls for residual non-specific binding (Figure 
3B). Similar, binding and uptake of the ACKR3-specific 
mAb 11G8 was abolished in ACKR3ko VAL cells either 
in culture or ex vivo (Figure 3C).
The chemotactic activity of ACKR3wt and ACKR3ko 
VAL cells in response to CXCL12 was tested by in vitro 
transmigration through human and mouse lymphatic 
endothelium (Figure 3D). Surprisingly, ACKR3 deletion 
in VAL cells markedly attenuated their chemotactic 
activity. However, when applied to ACKR3wt cells, 
indeed CCX771, but not the inactive compound CCX704, 
attenuated transendothelial migration. An inhibitory 
effect of CCX771 on the migration of ACKR3ko cells 
could not be detected due to their marginal response to 
CXCL12 (Figure 3E). The observation contrasts previous 
reports were it was shown that ACKR3 agonists such 
as CXCL11 or the small compound CCX771, which 
antagonize CXCL12 binding, but stimulate β-arrestin2 
recruitment, attenuate transendothelial migration (TEM) 
[50]. Noteworthy, in ACKR3ko VAL cells the receptor was 
absent and therefore unable to interact with arrestin.
Ablation of ACKR3 function reduces tumor cell 
infiltration
A localized xenograft model was used to study 
the role of ACKR3 in VAL DLBCL tumor spreading 
and tissue infiltration. Subcutaneous injection of 107 
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Figure 2: ACKR3 is functional on VAL cells. (A) ACKR3-dependent uptake of the fluorescent-labelled chimeric chemokine 
CXCL11_12 (left panel) and CXCL12 (right panel) (50 nM each, 1 h at 37°C) was analyzed by flow cytometry on ex vivo VAL cells. 
Cells were preincubated for 30 min with the ACKR3-blocking mAb 9C4 (30 μg/ml), the CXCR4 inhibitor NIBR1816 (5 μM), the CXCR4 
inhibitor AMD3100 (10 μM) or the anti-CXCR4 mAb 12G5 (30 μg/ml). Plots report mean percentages of Atto565 MFI ±SD of maximum 
uptake observed with 50 nM chemokine alone. Statistical analysis was performed with ANOVA one-way test *p<0.032, **p<0.019. 
Representative results of ex vivo VAL cells from two independent experiments performed in duplicates. (B) Surface binding and uptake of 
anti-ACKR3 mAb 11G8-PE by ex vivo and in culture VAL cells. Cells were incubated at 4°C 15 min and then incubation was continued for 
1h at 4°C or 37°C with the mAb. When indicated, surface bound 11G8-PE was removed with a brief acidic wash at pH=3. Samples analyzed 
by flow cytometry, one of three independent experiments is shown.
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ACKR3wt and ACKR3ko VAL cells into flanks of NOD/
SCID/common γ-chainko mice revealed no difference 
in local tumor growth (Figure 4A). Tumors became 
measurable with both cell types after 10 days and were 
followed for about three weeks. In general, cancer cells 
emigrate from local tumors via lymphatics and first 
signals of metastasis are found in the draining lymph 
nodes. Importantly, mice injected with ACKR3ko cells 
showed markedly lower frequency of infiltration of 
human CD19+ VAL cells into draining lymph nodes 
compared to animals injected with ACKR3wt VAL 
cells (Figure 4B). The observation suggests that tumor 
evasion and spreading of DLBCL VAL cells required 
ACKR3 expression. Previous data showed that systemic 
inhibition of CXCL12 scavenging by ACKR3 with small 
molecule antagonists, such as CCX754 and CCX771, 
caused markedly increased CXCL12 serum levels [24, 
51, 52]. In the present study ACKR3 was genetically 
deleted on the tumor cells while the receptors expressed 
on mouse tissue were not inhibited, suggesting that 
expression of ACKR3 on VAL cells was required 
for spreading via lymphatics but was independent of 
elevated CXCL12 levels. Collectively the reduced TEM 
observed in vivo and in vitro in the absence of ACKR3 
indicates a critical role for the receptor in controlling 
CXCR4-mediated cell migration.
Figure 3: Characterization of ACKR3ko VAL cells. (A) ACKR3 (mAb 9C4) and CXCR4 (mAb 12G5) surface expression on 
VAL cells grown in culture or extracted from localized tumors (ex vivo). One out of over 10 observations. (B) ACKR3wtand ACKR3ko 
VAL cells and the ACKR3 deficient pre-B cell line 300.19 (blank) were incubated at 37°C for 1 hour with the ACKR3-specific chimeric 
chemokine CXCL11_12 by. Uptake was measured by FACS as percentage of maximum uptake observed with 50 nM CXCL11_12, 
**p<0.001, n.s.= not significant, statistical analysis was performed with one-way ANOVA test. Representative plot from duplicates of 
three independent experiments. (C) Surface binding and uptake of mAb 11G8-PE by ACKR3wt and ACKR3koVAL cells kept in culture 
or extracted from localized tumors as in figure 2. Results of one of three independent experiments are shown (10 mice per group). 
(Continued )
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Ablation of ACKR3 limits organ infiltration in a 
disseminated xenograft model
It is well known that chemokine receptors can 
orchestrate organ-specific metastasis [53]. Disseminated 
xenograft models, in which cells are directly injected 
into the circulation, can be used to study the ability of 
neoplastic cells to colonize organs. In order to test the 
role of ACKR3 on the capability of VAL cells to infiltrate 
distant organs 2x105 ACKR3wt and ACKR3ko cells were 
injected intravenously into NOD/SCID/common γ-chainko 
mice. The tumor tissue infiltration was monitored daily for 
Figure 3 (Continued ): (D) Transendothelial migration of ex vivo VAL cells. VAL cell were allowed to migrate for 6h through pmLEC, 
primary mouse lymphatic endothelium and hLECs, human lymphatic endothelium. (E) Ex vivo ACKR3wtand ACKR3ko VAL cells were 
allowed to migrate for 6h through hLECs in the presence of 1μM CCX704 (inactive control) and CCX771. (D, E) Statistical analysis was 
performed with two-way ANOVA test. **p<0.01, ***p<0.001, n.s.= not significant.
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signs of neurologic disorders and when first symptoms of 
hind-leg paralysis (score 2) manifested all animals were 
sacrificed [54]. Mice injected with ACKR3wt and ACKR3ko 
VAL cells initially gained weight at a similar rate, but after 
about four weeks animals injected with wild type cells 
markedly lost weight (Figure 5A) which correlated with a 
remarkably higher clinical score at day of sacrifice (Figure 
5B). Organs typical for CXCL12/CXCR4-mediated tumor 
infiltration, such as bone marrow, brain, lungs and spleens 
were collected [53]. Organs were processed and stained 
for human CD19 as a marker for VAL cells and subjected 
to FACS analysis. Figure 5C shows that ACKR3wt VAL 
cells displayed a prominent invasion of multiple organs, 
which was most evident in bone marrow, followed 
by brain, lung and spleen. By contrast, all organs were 
markedly less infiltrated by the ACKR3ko VAL cells in line 
with the lower TEM capability. The cells extracted from 
the organs were also stained for mouse CD45 as a measure 
for host leukocytes in the tissues. In bone marrow the 
frequency of human CD19+ VAL inversely correlated with 
mouse CD45+ leukocytes depending on the expression of 
ACKR3 (Figure 6). The observation suggests that human 
ACKR3wt VAL cells efficiently compete for mouse CD45+ 
leukocyte niches in bone marrow. The competition was not 
observed in brain, lung and spleen (Figure 6). Neither was 
the frequency of mouse microglia cells altered in the brain.
In line with the FACs analyses (Figure 6), 
immunohistochemistry of paraffin embedded organs from 
mice injected with ACKR3wt VAL cells showed a higher 
degree of tissue infiltration compared to animals exposed 
to ACKR3ko VAL cells (Figure 7). The difference was 
most prominent in lymphoid organs. ACKR3wt VAL cells 
diffusely infiltrated the bone marrow almost completely 
replacing host hematopoiesis, whereas ACKR3ko VAL cells 
showed only local foci of invasion. Similarly, the spleen 
from mice injected with ACKR3 wild type cells displayed 
a widespread infiltration of CD20 positive lymphoma cells, 
in contrast to the spleen treated with ACKR3 deficient 
cells which displayed only a focal infiltration. In NOD/
SCID/common γ-chainko, which lack mature lymphocytes, 
lymph nodes are very small if at all detectable. However, 
in the systemic xenograft model of mice injected with 
ACKR3+ VAL cells, a few enlarged lymph nodes could be 
found, which were diffusely infiltrated with human CD20+ 
large lymphoma cells (Supplementary Figure 4). In the 
brain the difference in ACKR3-dependent infiltration of 
VAL cells was striking. While ACKR3ko VAL cells were 
almost absent in the brain, ACKR3wt VAL cells showed 
a predominant meningeal infiltration pattern, with foci of 
beginning parenchymal invasion at the day of sacrifice 
(Figure 7, 4x magnification).
In lung, both ACKR3wt and ACKR3ko cells were 
present, however ACKR3wt cells were more frequent 
(Figure 7). In the gastrointestinal tract only the stomach 
displayed some infiltration of VAL cells, which appeared 
slightly more prominent, when cells express ACKR3. By 
contrast, the lymphoma cells essentially spared the small 
intestine and colon (Supplementary Figure 4). Similarly, 
Figure 4: ACKR3 ablation does not affect local tumor growth but attenuates spreading to draining lymph nodes. (A) 
NOD/SCID/common γ-chainko mice (n=10) were injected subcutaneously with 107 VAL ACKR3ko and VAL ACKR3wt cells. Tumor volume 
was measured over time. Representative plot of one of three independent experiments. (B) Frequency of draining lymph nodes infiltrated 
with human CD19+ tumor cells. Cumulative results of three independent experiments. Statistical analysis was performed with two-tailed 
Student’s t-test. *p<0.1,**p<0.01, n.s.= not significant.
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Figure 5: Mice injected with VAL ACKR3ko cells show reduced loss of body weight, milder clinical manifestation and 
reduced organ invasion in a model of disseminated xenografts. (A) NOD/SCID/common γ-chainko mice were intravenously 
injected with 2x105 cells. Body weight variation over time. (B) Clinical scores of ACKR3koand ACKR3wt VAL cells disseminated xenografts. 
Cumulative results of three independent experiments. (C) Percentages of human VAL cells in total extracted cells. Human CD19+ were 
measured by flow cytometry. Three independent experiments with 9 or 10 mice per group, plots report mean ± SD of one representative 
experiment. p-value was calculated with two-tailed Student’s t-test. ***p<0.0001, **p<0.001, * p< 0.05, n.s.= not significant.
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only a marginal infiltration of the skin was observed 
(Supplementary Figure 4).
DISCUSSION
A continuously growing number of publications 
report elevated ACKR3 expression in many human 
cancers, including solid tumors and hematological 
malignancies [18, 28, 29, 33–35, 55]. Various mechanism 
have been proposed by which ACKR3 may sustain 
tumor development including promoting tumor growth, 
dampening apoptosis or favoring metastasis formation 
[20, 21, 23–27, 56]. Next to its scavenging activity, it is 
plausible that ACKR3-mediated signaling is responsible 
for the pathogenic role of the receptor. In line with this, 
it was recently proposed that stimulation of ACKR3 with 
CXCL12 leads to the activation of mTOR and Rho/ROCK 
pathways promoting cell migration and liver metastasis of 
pancreatic cancer cells [20].
Increased ACKR3 surface expression after in vivo 
passage or sorting of cells is not accompanied by elevated 
mRNA levels, suggesting a shift in receptor localization 
from endosomal structures to the cell surface. In line with 
this, preferential intracellular localization of ACKR3 has 
been reported [13, 40, 57–59]. However, an increase in 
ACKR3 protein levels is also possible. Nevertheless, 
several available mAb did not yield conclusive intracellular 
staining of ACKR3, in particular when ACKR3wt and 
ACKR3ko cells where compared. In addition, western blot 
analysis of membranes from ACKR3wt and ACKR3ko VAL 
cells were not decisive. Increased surface expression of 
ACKR3 was accompanied with enhanced scavenging 
activity (Figure 2B) demonstrating the functionality 
of the surface expressed receptor. Ligand induced and 
spontaneous internalization of ACKR3 requires an intact 
C-terminus [9, 58, 59] and arrestin binding [50, 60, 61]. 
ACKR3 does not bind G-proteins and was proposed to 
mediate arrestin-dependent signaling [62]. Moreover, 
the competitive agonist CCX771 stimulates arrestin 
recruitment at ACKR3, but efficiently blocked CXCL12/
CXCR4-mediated TEM [50]. The inhibitory effect on 
TEM was attributed to both, the expression of ACKR3 
Figure 6: Tissue invasion of VAL ACKR3ko and VAL ACKR3wt cells. NOD/SCID/common γ-chainko mice were injected with 
2x105 cells. Organs (bone marrow, brain, lung and spleen) were collected after four weeks and human CD19+ cells as well as mouse CD45+ 
leukocytes and in the brain mouse CD45low microglia counted by FACS in the extracts. Cumulative data from one out of three independent 
experiments with 10 animals per group. Statistical analysis was performed with Student’s t test. * p<0.01, ** p<0.001.
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Figure 7: Immunohistochemistry of tissue invasion by VAL ACKR3KO and VAL ACKR3wt cells. NOD/SCID/common 
γ-chainko mice were injected with 2x105 cells. Organs were removed after four weeks, formalin-fixed, paraffin-embedded 
and sections stained for CD20 (brown) expressing human VAL cells and counterstained with hematoxylin (blue).
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on endothelial cells as well as on the migrating tumor 
cells [50]. However, a possible ACKR3-mediated cell-
cell interaction or agonist-induced modulation of ACKR3 
signaling through arrestin were not excluded [50, 60].
The observation that ACKR3ko VAL cells showed 
markedly reduced CXCL12-stimulated TEM supports 
the assumption, that ACKR3 mediates a positive signal 
for CXCR4-mediated TEM through interaction with the 
endothelium. The fact that deletion of ACKR3 dampens 
CXCR4-mediated TEM (Figure 3D), argues against an 
inhibitory arrestin-dependent signaling by ACKR3. On 
the other hand, because CCX771 has agonistic effects on 
ACKR3 and enhances arrestin binding [50], it is possible 
that sequestration of arrestin for binding to CXCR4 leads 
to potential inhibition of TEM [60]. In line with this, 
arrestin binding to CXCR4 was reported to be required 
for CXCL12 dependent cell migration [63–65]. Again, 
the attenuated TEM of ACKR3ko VAL cells strongly 
argues against a direct ACKR3-arrestin mediated effect. 
A potential mechanism of ACKR3-mediated modulation 
of CXCR4 signaling could rely in allosteric regulation 
through multimerization, which may not require stable 
physical interactions, as often proposed for GPCR dimers, 
since both receptors can internalize independently [66–
68]. In fact, it was shown, that ACKR3 and CXCR4 co-
expression can enhance CXCL12-stimulated migration in 
an arrestin dependent manner [68].
Malignant cells often upregulate chemokine 
receptors allowing tissue specific homing of circulating 
tumor cells of solid cancers [1, 53] and of several 
lymphoma subtypes [69]. The typical chemokine receptor 
CXCR4 is present in many cancers and is responsible 
for metastasis formation in several organs [1]. The 
concomitant expression of ACKR3 appears sufficient to 
alter CXCR4-mediated tissue specific metastasis pattern 
in disseminated xenografts [26, 70]. DLBLC are known 
to invade the bone marrow and the CNS as well as other 
extranodal sites [38, 39]. The present results obtained with 
a xenograft model of the DLBCL cell line VAL show that 
ACKR3 expression is necessary for brain infiltration. In 
analogy with the poor prognosis of CNS infiltration by 
DLBCL in humans, mice injected with ACKR3wt VAL 
cells showed a worse clinical score compared to animals 
injected with cells in which ACKR3 was genetically 
deleted. The observation is further supported by the in 
vitro observation that deletion of ACKR3 reduced the 
capability of the cells to transmigrate endothelial layers 
in response to CXCL12. Conditioning of the cells in mice 
lead to the upregulation of surface expression of ACKR3 
which may additionally promote the aggressiveness of the 
cells in vivo.
Similarly, in the localized xenograft model ACKR3 
expression correlated with invasion of draining lymph 
nodes, underlining the role of ACKR3 for cell mobility 
and aggressiveness of lymphoma. Several studies illustrate 
the ability of atypical receptors, such as ACKR3 and 
ACKR4, to create functional chemokine gradients [7, 13, 
14]. Antagonizing scavenging activity of ACKR3 with 
small molecules or genetic deletion may interfere with the 
formation of local CXCL12 cues attenuating lymphoma 
cell dissemination. Taken together, the data unveil ACKR3 
as a potential therapeutic target for DLBCL.
MATERIALS AND METHODS
Cell lines and cell culture
DLBCL cell lines were as previously described 
[71]. VAL and Karpas422 cells were cultured in RPMI-
1640 medium complemented with 10% heat-inactivated 
FBS, 1% Penicillin/Streptomycin, 1% GlutaMAX. OCI-
LY19, OCI-LY8, and the mouse pre-B cell line 300.19 
were cultured in same medium supplemented with 1% 
non-essential aminoacids, 1% sodium Pyruvate, and 
50μM β-mercaptoethanol. RIVA and SUDHL16 cells 
were cultured with IMDM, 10% heat-inactivated FBS, 
1% Penicillin/Streptomycin. All media and supplements 
were purchased from Thermo Fisher Scientific. Human 
dermal lymphatic microvascular endothelial cells (hLECs) 
(Lonza) and primary murine lymphatic endothelial cells 
(pmLECs) where donated by Dr. Cornelia Halin Winter 
(ETH, Zurich). The hLECs were cultured in EBM-2 
medium without VEGF-A (EGM-2 MV BulletKit Lonza); 
pmLECs where cultured in 40% DMEM (low glucose), 
40% F12-Ham, 20% FBS (Thermo Fisher Scientific), 56 
μl/ml heparin (Sigma), 10 μl/ml endothelial cell mitogen 
(Bio-Rad), cAMP (25 μg/ml), hydrocortisone (10 μg/ml) 
antibiotic/antimycotic solution (Sigma), and L-glutamin (2 
mM, Sigma). Both, hLECs and pmLECs where cultured 
on dishes coated with collagen (10 μg/ml, PureCol, 
Advanced Biomatrix) and collagen plus fibronectin 
(MerkMillipore), respectively. All cells were cultured at 
37°C with 5% CO2.
Transmigration assay
The hLECs and pmLECs where cultured as 
monolayer on Transwell® migration plates (5μm pores size, 
Corning). VAL cells (106/ml) were resuspended in RPMI-
1640 supplemented with 25mM HEPES, 1% FBS and 1% 
penicillin/streptomycin and added on top of endothelial 
cells. CXCL12 was diluted in medium supplemented with 
10% FBS at the indicated concentrations and added to 
the lower compartments. Plates were incubated at 37°C 
for 6h. Migrated cells were recovered from the lower 
compartments and counted by flow cytometry.
FACS analysis and cell sorting
Cells in FACS buffer (phosphate buffered saline 
(PBS) 2% FBS, 0.05% sodium azide) were stained for 15-
30 min on ice with the appropriate antibodies. Cells were 
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analyzed with a Becton & Dickinson (BD) LSRFortessa 
or FACSCanto I cytometers and FlowJo software. For 
sorting cells were stained with appropriate Abs, washed 
with FACS buffer and resuspended in PBS 2% FBS, 2 mM 
EDTA, filtered through a cell strainer and sorted with BD 
FACSAria IIIu.
Antibodies
The following antibodies were used for FACS 
staining: anti-human ACKR3 clone 9C4 (IgG1) and 
anti-human CXCR4 clone 12G5 (IgG2a) as previously 
described [48] and counterstained with isotype specific 
goat antibodies (Southern Biotech). Anti-human ACKR3 
clone 11G8-PE was purchased from R&D systems, anti-
human CD19-PE-Cy7 clone SJ25C and anti-human 
CXCR4-PE clone 12G5 from BD Pharmingen and anti-
mouse CD45-APC-Cy7 clone 30-F11 from BioLegend.
Semi-quantitative and quantitative PCR
Total RNA was isolated with TRIzol Reagent 
(Ambion) and RNA concentration was determined. 
Reverse transcription of 2 μg of RNA was performed 
with the Superscript Vilo kit following the manufacturer’s 
instructions (Thermo Fisher Scientific). The following 
primers were used for semi-quantitative PCR and real time 
(RT)-PCR:
ACKR3 - 5’-ATGGATCTGCATCTCTTCGAC-3’ 
and 5’-GTAGCGGTCCACGCTCATGC-3’, β-Actin 
5’-TCACCCACACTGTGCCCATCTACGA-3’ and 
5’-CTAGAAGCATTTGCGGTGGACGATGG-3’. 
Amplification of cDNA obtained from ex vivo VAL cells 
was performed after CD19+ cells enrichment by magnetic 
separation with anti-human CD19 microbeads (MACS, 
Miltenyi Biotec). qPCR was performed using the PerfeCta 
SYBR Green FastMIX (ROX) (Quanta Bioscience) on 
MicroAmp Fast Optical 96-well Reaction plate (Applied 
Biosystem). Expression of the TATA-box binding protein 
(TBP1) was used as control: 5’GTTCTGGGAAAATGG
TGTGCACAGGAGCCAAG3’ and 5’GCTGGAAAACC
CAACTTCTGTACAACTCTAGC3’. Data were analyzed 
by means of ΔCt values and ACKR3 expression was 
calculated as mean difference of ACKR3 Ct values minus 
mean TBP1 ΔCt value, expressed as 2-ΔCt.
Uptake assay of fluorescently labelled 
chemokines and anti-ACKR3 antibody
VAL cells were pre-incubated for 10 min at 37°C 
with the CXCR4 inhibitors AMD3100 (10 μM, Sigma-
Aldrich) and the isothiourea 1a NIBR-1816 5 μM (kind 
gift from H.G. Zerwes, Novartis) [46], and the monoclonal 
antibodies 12G5 (anti CXCR4) 30 μg/ml, 9C4 (anti-
ACKR3) 30 μg/ml. Cells were then incubated with 
medium alone or 50 nM chimeric chemokine or CXCL12 
in the presence of absence of the inhibitors for 1 h at 37°C. 
Recombinant chemokines were produced and labelled as 
described [45]. Reactions were terminated by washing 
with PBS containing 2% FBS and cells subjected to a brief 
acidic wash [48]. For the antibody uptake assay, cells were 
incubated with α-human ACKR3 mAb 11G8-PE (1:100 
diluted from commercial stock) at 4°C or at 37°C for 1 
hour. Samples were briefly washed at low pH [48] and 
resuspended in FACS buffer analysis.
ACKR3 gene knock out
CRISPR/Cas9 mediated gene editing of 
ACKR3 was performed by transfecting VAL 
cells with either of two guideRNA-Cas9 vectors 
(U6gRNA-Cas9-2A-RFP, Sigma) with target 
sites TCTTCGACTACTCAGAGCCAGG and 
AACAGCAGCGACTGCATCGTGG respectively 
in combination with a HDR-repair construct (in 
pUC57-Kan, Sigma) introducing CFP under the 
SFFV promotor. Briefly, two million VAL cells were 
nucleofected (Nucleofection Kit V, Lonza) with 1 µg 
guideRNA-Cas9 vector plus 4 µg NdeI-linearized 
HDR-repair plasmid (program X 01). Two days after 
transfection red fluorescent protein (RFP) positive 
cells were enriched by FACS-sorting and cultured for 
one week. Nucleofection was repeated with the second 
guideRNA-Cas9 vector plus the HDR-construct. 
After RFP-FACS enrichment, cells were cultured 
for one week followed by single cell sorting. Clones 
were tested for successful knock down of the ACKR3 
gene by genomic PCR using the following primers: 
5’CAATGGTACCCCGTGGCTGAATTC3’ forward 
and 5’TTGCTCTAGAAAACCATAGGGCCCATC3’ 
reverse. One out of seven clones showed a single 
PCR product of 3311 nucleotides corresponding to the 
successful integration of the HDR-repair construct in 
both alleles, which was confirmed by sequencing.
Mice and mouse models
All animal experiments were performed in 
accordance with the Swiss Federal Veterinary Office 
guidelines and authorized by the Animal Studies 
Committee of Cantonal Veterinary. Genetically 
immunosuppressed NOD.Cg-Prkdcscid IL2rgtm1wjlI SzJ 
were purchased from Jackson Laboratory and bred in a 
specific-pathogen free facility. Mice, 6-8 weeks-old, were 
injected subcutaneously with 107 VAL cells in PBS in 
order to create localized xenografts. Tumor growth was 
monitored daily, and when the tumors were palpable, they 
were measured with a digital caliper. Tumor volumes were 
calculated with the following formula: V= length x width2 
x 0.5. Disseminated xenografts were produced through 
intravenous injection in the tail vein of 2x105 Val cells 
in PBS. Mice were monitored daily and clinical scores 
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were assessed as follow: Score 0 = no signs of discomfort, 
Score 1 = slight movement impairment, Score 2 = hind leg 
paralysis. Mice were latest sacrificed at score 2.
Tumor processing and leukocyte isolation
Localized xenografts were surgically removed, 
and mechanically disintegrated between 150 μm Sefar 
Nitex filters. Cells were washed and cultured. In the 
disseminated xenograft model, mice were sacrificed 
and extensively perfused with PBS. Femurs, tibiae, 
lungs, spleen and brain were collected. Bone marrow 
cells were recovered from femurs and tibiae by gentle 
centrifugation and filtration. Lungs were minced with 
surgical scissors and digested with 0.05 mg/ml liberase 
(TL Research Grade) and 1 mg/ml DNase I (Sigma) in 
PBS for 1 h at 37°C. The digestion was terminated by the 
addition of medium and the cells separated from stroma 
by filtration. Brains were disintegrated between filters 
and incubated with 1 mg/ml DNase I and 125 μg/ml 
collagenase IV (Sigma) at 37°C for 30 min under 
agitation. For leukocyte isolation the cell suspension 
was filtered and mixed with 30% Percoll for leukocyte 
isolation by centrifugation was performed at 4°C and 
353 x g for 20 min.
Histology and immunohistochemistry
For histopathological analysis organs from 
mice from disseminated xenograft tumor models were 
harvested, rinsed with PBS and placed in 4% neutral 
buffered formalin (Thermo Scientific). Tissue specimens 
were embedded in paraffin. Paraffin sections (4 μm) 
were stained with hematoxylin and eosin (H&E). For 
immunohistochemical analysis, slides from all organs 
sampled (bone marrow, brain, lung, spleen, stomach, 
kidney, small and large intestines, lymph nodes and 
skin) were stained with a monoclonal mouse anti-human 
CD20 antibody (clone L26, prediluted, Ventana Medical 
Systems, Tucson, Ariz., USA). Following pretreatment 
according to the manufacturer's protocols, the slides 
were incubated at room temperature on an automated 
immunostainer (BenchMark XT, Ventana Medical 
Systems, Tucson, Ariz., USA). Antigen detection was 
performed using a commercial detection kit (UltraView 
Detection Kit; Ventana) with diaminobenzidin as the 
chromogen.
Statistical analysis
All data are expressed as mean (±SD) and where 
analyzed with SigmaPlot. Statistical analyses were 
performed with two-tailed Student’s t-test or one-way 
ANOVA test. Two-sided p values less than 0.5 were 
considered significant.
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